BeiGene, Ltd. (ONC)

Market Cap	18.94B
Revenue (ttm)	3.35B
Net Income (ttm)	-854.42M
Shares Out	106.47M
EPS (ttm)	-8.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251,011
Open	175.00
Previous Close	175.10
Day's Range	172.67 - 177.99
52-Week Range	126.97 - 248.16
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 24, 2025

About ONC

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10,600
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://www.beigene.com

Financial Performance

In 2023, BeiGene's revenue was 2.46 billion, an increase of 73.65% compared to the previous year's 1.42 billion. Losses were -881.71 million, -56.00% less than in 2022.

Financial numbers in CNY